Browse studies

Find your next paid study

55 recruiting studies matching your filters

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed to…

Prostate CancerBreast CancerNeuroendocrine Tumors

Estimated

~$10 – $750

Actual pay is set by the research site.

University of California, DavisNCT05160480

Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Background: Pheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region. Not all these tumor…

PheochromocytomaParagangliomaNeuroendocrine Tumors+1 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT03206060

Phase 2

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable,…

Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)

Estimated

~$75 – $3,000

Actual pay is set by the research site.

ExelixisNCT06943755

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Background: * Endocrine neoplasms (tumors) are among the fastest growing tumors in incidence in the United States. Furthermore, it is often difficult to disti…

Endocrine TumorsThyroid NeoplasmsParathyroid Neoplasms+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT01005654

Phase 2

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the lab…

Metastatic Colorectal CancerMetastatic Pancreatic CancerMetastatic Ovarian Cancer+2 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT01174121

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Background: Neuroendocrine neoplasm (NENs)are rare cancers arising from the neuroendocrine cells and can affect almost any part of the body. They vary from lo…

Neuroendocrine TumorsCarcinoma, Neuroendocrine

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05237934

Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, gr…

MelanomaAdenocarcinomaCarcinoma NOS+1 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT00923026

Phase 2

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic n…

Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau Disease+2 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLC

Phase 1

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pan…

Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05687123

Phase 2

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor…

Advanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine TumorLocally Advanced Lung Neuroendocrine Neoplasm+9 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

Phase 2

The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers

The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers

Neuroendocrine TumorsGynecologic Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of UtahNCT07151391

Phase 4

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor a…

Digestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Neoplasm+3 more

Estimated

~$25 – $1,000

Actual pay is set by the research site.

Vanderbilt-Ingram Cancer CenterNCT06016855